Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 57(2): 1053-6, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23183438

ABSTRACT

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.


Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/therapeutic use , HIV Reverse Transcriptase/genetics , Organophosphonates/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adenine/therapeutic use , Adult , Drug Resistance, Viral/genetics , Drug Therapy, Combination , Female , Genetic Variation , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/classification , HIV-1/drug effects , HIV-1/enzymology , HIV-1/genetics , Humans , Male , Middle Aged , Molecular Sequence Data , RNA-Directed DNA Polymerase/genetics , Reverse Transcriptase Inhibitors/pharmacology , Tenofovir
2.
HIV Med ; 12(4): 211-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20731728

ABSTRACT

OBJECTIVES: The EuResist expert system is a novel data-driven online system for computing the probability of 8-week success for any given pair of HIV-1 genotype and combination antiretroviral therapy regimen plus optional patient information. The objective of this study was to compare the EuResist system vs. human experts (EVE) for the ability to predict response to treatment. METHODS: The EuResist system was compared with 10 HIV-1 drug resistance experts for the ability to predict 8-week response to 25 treatment cases derived from the EuResist database validation data set. All current and past patient data were made available to simulate clinical practice. The experts were asked to provide a qualitative and quantitative estimate of the probability of treatment success. RESULTS: There were 15 treatment successes and 10 treatment failures. In the classification task, the number of mislabelled cases was six for EuResist and 6-13 for the human experts [mean±standard deviation (SD) 9.1±1.9]. The accuracy of EuResist was higher than the average for the experts (0.76 vs. 0.64, respectively). The quantitative estimates computed by EuResist were significantly correlated (Pearson r=0.695, P<0.0001) with the mean quantitative estimates provided by the experts. However, the agreement among experts was only moderate (for the classification task, inter-rater κ=0.355; for the quantitative estimation, mean±SD coefficient of variation=55.9±22.4%). CONCLUSIONS: With this limited data set, the EuResist engine performed comparably to or better than human experts. The system warrants further investigation as a treatment-decision support tool in clinical practice.


Subject(s)
Expert Systems , HIV Infections/drug therapy , HIV-1/drug effects , Databases, Factual , Female , HIV Infections/genetics , HIV Infections/virology , HIV-1/genetics , Humans , Male , Probability , Treatment Outcome , Viral Load
3.
Eur J Med Res ; 15(5): 225-30, 2010 May 18.
Article in English | MEDLINE | ID: mdl-20562063

ABSTRACT

The success of first-line antiretroviral therapy can be challenged by the acquisition of primary drug resistance. Here we report a case where baseline genotypic resistance testing detected resistance conferring nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-associated mutations, but no primary mutations for protease inhibitor (PI). Subsequent PI-based HAART with boosted saquinavir led to virological treatment success with persistently undetectable viral load. After treatment simplification from saquinavir to an atazanavir based PI-therapy and no change in backbone therapy rapid virological breakthrough occurred. Retrospective analysis displayed preexisting gag cleavage site mutations which may have reduced the genetic barrier in a clinical relevant manner in combination with the already existing NRTI resistance mutations. Alternatively, this effect could be explained with a different antiviral potency for the respective PIs used.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Mutation , Reverse Transcriptase Inhibitors/pharmacology , Adult , Drug Resistance, Viral , Female , HIV-1/genetics , Humans , Zidovudine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...